News of Note—Dynavax, Emergent BioSolutions and more

In this week's News of Note, Dynavax steadily grew sales of its novel hepatitis B vaccine, Heplisav-B. (Pixabay)

Here is some other vaccine news of note for the week:

> Dynavax’s hepatitis B vaccine Heplisav-B sold $1.3 million in the second quarter, up from $0.2 million in the first quarter. Release

> Emergent BioSolutions posted second-quarter revenue of $220 million, an increase of 118% year over year, thanks to sales of anthrax vaccine BioThrax and smallpox vaccine ACAM2000. Release

> Changchun Changsheng Life Sciences, embroiled in China’s latest vaccine scandal, was found to have forged production data for more than four years. Xinhua article

> The International AIDS Vaccine Initiative reached a nonexclusive license agreement with the Public Health Agency of Canada to obtain vesicular stomatitis virus vector technology for a Lassa fever vaccine currently under funding from the Coalition for Epidemic Preparedness Innovations. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.